A biotech developing targeted cancer pills, including a first commercial drug for a rare leukemia and earlier-stage candidates for solid tumors. Think of it as a precision-medicine startup aiming to outsmart cancer's genetic switches.
No real profit engine yet: annual revenue is just USD 0.07B, mostly from early drug sales, while net losses run about USD 0.28B per year. Gross margins are near 100%, but heavy R&D spending means the business burns cash rather than earns it.
Its menin-inhibitor platform is protected by patents and clinical data, making it hard for generic drugmakers to copy. But larger rivals like Pfizer and Novartis are advancing similar menin-targeting drugs, which could erode Kura's first-mover edge in leukemia
None yet
None yet
Kura Oncology's CEO made a significant insider purchase, signaling confidence amid positive momentum from recent calls and upcoming pipeline catalysts.
Main discussion
Different voices
Nice $1.1M insider buy from $KURA CEO today, +6% AH after a strong trading day(s) Too cheap for the oppty; call was great $STIM $STLN also with insider buys today. Port is just rolling in it rn
$KURA CEO buys 1.1 million worth at $11.12 after very strong call last week - momentum building on launch/pipeline
$KURA catalysts 2H 2026, long-term KOMET-007 data for zifto + ven/aza in ND NPM1m AML, 2) initial KOMET-007 data for zifto + 7+3 + quizartinib in ND NPM1m/FLT3-ITD AML, 3) initial KOMET-008 data for zifto+gilteritinib in r/r NPM1m/FLT3m AML, and 4) exploratory zifto mono analysis
$KURA https://www.sec.gov/Archives/edgar/data/1422143/000119312526354201/xslF345X06/ownership.xml
Options with increasing option implied volatility: $PYPL $KURA $VICI $PGEN $PYPL $EQX $IEP $TMV $TRMD $TMF $CZR
$KURA https://t.co/ImMtIVAKdL
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
